Denali Therapeutics Inc DNLI:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 3:55 PM EDT
19.23quote price arrow down-0.83 (-4.14%)
Volume
613,417
52 week range
14.56 - 33.31
Loading...
  • Open20.11
  • Day High20.11
  • Day Low18.89
  • Prev Close20.06
  • 52 Week High33.31
  • 52 Week High Date06/16/23
  • 52 Week Low14.56
  • 52 Week Low Date04/25/24

Key Stats

  • Market Cap2.742B
  • Shares Out142.61M
  • 10 Day Average Volume0.87M
  • Dividend-
  • Dividend Yield-
  • Beta1.39
  • YTD % Change-10.48

KEY STATS

  • Open20.11
  • Day High20.11
  • Day Low18.89
  • Prev Close20.06
  • 52 Week High33.31
  • 52 Week High Date06/16/23
  • 52 Week Low14.56
  • 52 Week Low Date04/25/24
  • Market Cap2.742B
  • Shares Out142.61M
  • 10 Day Average Volume0.87M
  • Dividend-
  • Dividend Yield-
  • Beta1.39
  • YTD % Change-10.48

RATIOS/PROFITABILITY

  • EPS (TTM)-0.97
  • P/E (TTM)-19.90
  • Fwd P/E (NTM)-7.15
  • EBITDA (TTM)-199.295M
  • ROE (TTM)-11.33%
  • Revenue (TTM)295.39M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-46.46%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Denali Therapeutics Inc

 

Profile

MORE
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage...
Vicki Sato Ph.D.
Independent Chairman of the Board
Ryan Watts Ph.D.
President, Chief Executive Officer, Director
Alexander Schuth M.D.
Chief Financial Officer, Chief Operating Officer, Company Secretary
Address
161 Oyster Point Blvd
South San Francisco, CA
94080-1910
United States

Top Peers

SYMBOLLASTCHG%CHG
TWST
Twist Bioscience Corp
41.32-1.77-4.11%
TGTX
TG Therapeutics Inc
16.96-0.73-4.15%
IMCR
Immunocore Holdings PLC
47.99-2.48-4.91%
MOR
MorphoSys AG
18.33+0.03+0.16%
FOLD
Amicus Therapeutics Inc
9.47-0.25-2.52%